Compare ORCL & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORCL | NVS |
|---|---|---|
| Founded | 1977 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | 75267 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 865.6B | 310.4B |
| IPO Year | 2005 | N/A |
| Metric | ORCL | NVS |
|---|---|---|
| Price | $149.47 | $164.81 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 33 | 4 |
| Target Price | ★ $298.27 | $118.00 |
| AVG Volume (30 Days) | ★ 22.4M | 2.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 1.34% | ★ 1.89% |
| EPS Growth | ★ 16.98 | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $57,399,000,000.00 | N/A |
| Revenue This Year | $19.00 | $2.65 |
| Revenue Next Year | $29.42 | $4.76 |
| P/E Ratio | $47.99 | ★ $23.13 |
| Revenue Growth | ★ 8.38 | N/A |
| 52 Week Low | $119.00 | $97.72 |
| 52 Week High | $345.72 | $170.46 |
| Indicator | ORCL | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | 59.59 |
| Support Level | $136.92 | $111.47 |
| Resistance Level | $165.39 | N/A |
| Average True Range (ATR) | 6.67 | 2.12 |
| MACD | 1.13 | -0.40 |
| Stochastic Oscillator | 42.85 | 48.23 |
Oracle provides enterprise applications and infrastructure offerings around the world through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used for running online transaction processing and data warehousing workloads. Besides database systems, Oracle also sells enterprise resource planning, or ERP, customer relationship management, or CRM, and human capital management, or HCM, applications. Today, Oracle has more than 159,000 full-time employees in over 170 countries.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.